Cowen Downgrades Aegerion Pharmaceuticals (AEGR) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Aegerion (AEGR) Q1 Juxtapid Sales 'Surprisingly Weak', Jefferies Says
May 7, 2014 9:00 AM EDTJefferies analyst Eun K. Yang, Ph.D lowered his price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) to $61.00 (from $80.00) following 'surprisingly' weak Q1 Juxtapid sales.
Yang comments, "While AEGR is confident of meeting its ~5% lowered guidance ($180M-$200M), surprisingly weak 1Q14 Juxtapid... More
Aegerion (AEGR) PT Lowered to $70 at Deutsche Bank Due to Slow Patient Growth
May 7, 2014 8:37 AM EDTDeutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) an reduced its price target to $70.00 (from $115.00). Analyst Robyn Karnauskas expressed caution due to slow patient growth.
"Juxtapid 1Q revenues at $27M were lower than consensus at $33.6M primarily due to lower sales in ex-US.... More
Aegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 10c
May 6, 2014 4:34 PM EDTAegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q1 EPS of ($0.25), $0.10 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $27 million versus the consensus estimate of $33.58 million.
Highlights
Aegerion achieved $27.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the first-quarter of 2014. 96% of net product sales in the first quarter were from the United States business, representing growth of 24% over net product sales from the U.S. business in the prior quarter. The Company now expects to achieve between $180 million and $200 million of net product sales... More